Biotech Adam Feuerstein STAT Plus: The NASH race: A fleeting frontrunner, a stumbling giant, and others in biotech look to the finish line
Biotech Adam Feuerstein STAT Plus: A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial
Adam's Take Adam Feuerstein STAT Plus: Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble
